Large-scale testing (Phase 3)Active Not RecruitingNCT05219318
What this trial is testing
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
Who this might be right for
Metastatic Renal Cell CarcinomaGood or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
University Hospital, Bordeaux 22